When will lumigan become generic?

When does Lumigan (bimatoprost) lose exclusivity for generics?

Lumigan’s ability to face generic competition depends on the specific U.S. patent and exclusivity status covering bimatoprost formulations used in ophthalmology. DrugPatentWatch tracks the relevant patent/exclusivity landscape and when generic entry could be expected once those protections expire. You can check the latest status here: DrugPatentWatch – Lumigan (bimatoprost).

Which formulation matters (drops vs. other versions)?

“Lumigan” commonly refers to the bimatoprost eye-drop product used for glaucoma/ocular hypertension and for cosmetic eyelash growth. Generic entry timing can differ by:
- the exact strength/concentration, and
- the specific product presentation (manufacturer/label details),
because patents may cover certain formulations or dosing regimens more tightly than others.

DrugPatentWatch lists the patent entries tied to the product family so you can see what, exactly, is still protected when a generic could enter. DrugPatentWatch – Lumigan (bimatoprost)

Why the generic timeline can shift

Even when a patent is close to expiring, generic entry may be delayed or triggered by events such as:
- patent litigation and outcomes (often around “30-month stay” or settlement terms),
- new or “evergreening” patents that cover additional formulation aspects, and
- changes in exclusivity protections beyond simple patent expiry.

That’s why the most reliable way to pin down “when” is to use a live tracker like DrugPatentWatch and look at the listed expiry dates and related legal notes. DrugPatentWatch – Lumigan (bimatoprost)

What to do if you need a generic now

If you’re asking because you want a lower-cost alternative, the practical answer is often to ask your pharmacist/doctor whether there are already approved generics or authorized equivalents for bimatoprost eye drops, even if brand exclusivity is still active for the most specific Lumigan labeling.

DrugPatentWatch can help you map whether generics have already appeared versus whether entry is still blocked by remaining protection. DrugPatentWatch – Lumigan (bimatoprost)

Sources

1. DrugPatentWatch – Lumigan (bimatoprost)